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Abstract
Background: Group B streptococcus (GBS) is a leading cause of sepsis, pneumonia and meningitis in infants, with
long term neurodevelopmental sequelae. GBS may be associated with poor pregnancy outcomes, including
spontaneous abortion, stillbirth and preterm birth. Intrapartum antibiotic prophylaxis (IAP) is currently the only way
to prevent early-onset disease (presenting at 0 to 6 days of life), although it has no impact on the disease
presenting over 6 days of life and its implementation is challenging in resource poor countries. A maternal vaccine
against GBS could reduce all GBS manifestations as well as improve pregnancy outcomes, even in low-income
countries.
Main body: The term “PREPARE” designates an international project aimed at developing a maternal vaccination
platform to test vaccines against neonatal GBS infections by maternal immunization. It is a non-profit, multi-center,
interventional and experimental study (promoted by the St George University of London. [UK]) with the aim of
developing a maternal vaccination platform, determining pregnancy outcomes, and defining the extent of GBS
infections in children and mothers in Africa. PREPARE also aims to estimate the protective serocorrelates against the
main GBS serotypes that cause diseases in Europe and Africa and to conduct two trials on candidate GBS vaccines.
PREPARE consists of 6 work packages. In four European countries (Italy, UK, Netherlands, France) the recruitment of
cases and controls will start in 2020 and will end in 2022. The Italian PREPARE network includes 41 centers. The
Italian network aims to collect: GBS isolates from infants with invasive disease, maternal and neonatal sera (cases);
cord sera and GBS strains from colonized mothers whose infants do not develop GBS infection (controls).
Short conclusion: PREPARE will contribute information on protective serocorrelates against the main GBS serotypes
that cause diseases in Europe and Africa. The vaccine that will be tested by the PREPARE study could be an
effective strategy to prevent GBS disease.
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Background
Group B streptococcus (GBS or Streptococcus agalactiae)
is a Gram-positive pathogen belonging to Lancefield
group B. It is a common commensal of the gastrointestinal
tract and colonizes 10–30% of pregnant women at vaginal
or vaginal/rectal sites [1]. In pregnant women, GBS is a
frequent causative agent in urinary tract infections, chor-
ioamnionitis and postpartum endometritis, and it is also
associated with poor pregnancy outcomes, including
spontaneous abortion, stillbirth and preterm birth [2].
GBS is a leading cause of sepsis, pneumonia and men-
ingitis in infants, with long-term neurodevelopmental se-
quelae. Neonatal GBS infections are usually divided into
Early-Onset Disease (EOD, presenting at 0 to 6 days of
life) and Late-Onset Disease (LOD, presenting at 7 to
90 days of life) [3]. EOD is prevented through intrapar-
tum antibiotic prophylaxis (IAP) in women with GBS
colonization or obstetrical risk factors for GBS vertical
transmission.
Main text
The term “PREPARE” designates an international project
entitled “Prevention of invasive Group B Streptococcus
disease in young infants: a pathway for the evaluation &
licensure of an investigational maternal GBS vaccine”.
PREPARE is aimed at developing a vaccine against neo-
natal GBS infections and is promoted by the St George
University of London (UK) (see https://gbsprepare.org).
This project is part of the EDCTP2 program (Euro-
pean & Developing Countries Clinical Trials Partner-
ship) that funds research for prevention and treatment
of poverty-related infectious diseases in sub-Saharan Af-
rica and it is aligned with the WHO roadmap [1]. More-
over, PREPARE is supported by Horizon 2020
(European Union’s Framework Program for Research
and Innovation).
Strategies implementing IAP, especially those that
screen women in late pregnancy for vagino-rectal GBS
colonization (regardless of presenting risk factors) has
led to a dramatic decline in the incidence rates of EOD
(i.e., from 0.37 to 0.22 per 1000 live births from 2006 to
2017 in USA) [4]. However, IAP coverage is incomplete
even in the best of settings. Furthermore, the burden of
invasive GBS disease may be high in resource poor
countries such as Africa (estimated incidence of 1.12/
1000 live births) where IAP implementation is challen-
ging [5]. Concerns have arisen as to the possible negative
impact of large-scale prevention, as IAP may promote
the emergence of antibiotic resistance, and early expos-
ure to antibiotics can disrupt the development of the in-
testinal microbiome, with consequences in adulthood
[6]. Finally, IAP has no impact on LOD, stillbirths and
prematurity due to GBS, as well as a limited impact on
disease in pregnant women [7]. Further strategies are
urgently required to decrease GBS-associated morbidity
and mortality.
There are ten known GBS serotypes (Ia, Ib and II-IX),
but serotype Ia, III and V are more commonly respon-
sible of invasive GBS disease in infants under 90 days of
life. Multivalent vaccines administered to pregnant
women to protect their infants against GBS disease
could overcome many of the outstanding issues related
to IAP and could be an effective strategy for resource-
poor countries. Indeed, compared to WHO European re-
gion, in WHO African region mortality rates are 7 times
higher (7/1000 vs 51/1000 LBs) [8].
Therefore, the prevention of neonatal infections
through maternal immunoprophylaxis is a topic that has
recently aroused wide attention. The purpose of this
strategy is to induce maternal protective immunity
resulting in a specific transplacental IgG passage. Indeed,
recent data have shown that vaccinating pregnant
women does not increase adverse events or fetal risks
[9]. WHO data from developing countries show a 92%
decline (from the 1980s to 2000) in neonatal tetanus
case fatalities following maternal vaccination with tet-
anus toxoid [10].
It is estimated that to detect a 75% reduction in EOD
and LOD in countries with a disease incidence of more
than 1/1000 births it would be necessary to enroll about
60,000 pregnant women to study the effectiveness of the
vaccine, assuming that this protects from 90% of circu-
lating serotypes [11]. Therefore, in order to facilitate the
licensure of a vaccine, the study of protective serocorre-
lates, followed by a demonstration of a post-license effi-
cacy, aroused interest. Although previous studies have
shown an association between serotype-specific maternal
IgG titers and reduction of neonatal disease risk, no
study has been able to establish with certainty a protect-
ive antibody threshold value, due to different assays for
determining antibody titers or inability to compare and
pool the results of different studies [12]. Vaccines have
been tested against serotype-specific capsular polysac-
charide and against surface proteins that are expressed
in different serotypes and could then protect against spe-
cific serotypes [7, 12].
PREPARE is a non-profit, multi-center, interventional
and experimental study. It aims to develop a maternal
vaccine platform in Uganda, determine pregnancy out-
comes and to define the extent of GBS infections in chil-
dren and mothers in a sub-Saharan context. It also aims
to estimate the protective serocorrelates against the
main GBS serotypes that cause diseases in Europe and
Africa and to conduct two trials on candidate GBS vac-
cines. The PREPARE project involves 7 countries across
the world (Malawi, Uganda, South Africa, the United
Kingdom, the Netherlands, Italy and France) and aims
to develop a serum biobank, in order to define
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serocorrelates of protection against GBS, by using stan-
dardized antibody assays and a bacterial strains bank to
study the characteristics of neonatal and maternal
strains.
The overarching objectives will be achieved through 6
work packages (WPs), each with specific aims (Table 1).
Italy (that belongs to WP3) is represented by a network
made up of 41 centers across the country (Table 2), co-
ordinated by the Azienda Ospedaliero-Universitaria Poli-
clinico (Modena). The Italian network will collect at
least 50 neonatal GBS invasive cases (defined as an in-
fant with isolation of GBS from blood culture or from
culture of cerebro-spinal fluid) within 2 years. Strains
will be sent to the national referring center (Istituto
Superiore di Sanità) for GBS typing.
The PREPARE Italian network will collect: i) isolates
from infants with invasive disease (cases), together with
maternal and neonatal sera collected at the time of diag-
nosis of infant disease; ii) cord sera and GBS strains (of
the same serotype as cases) from colonized mothers
whose infants do not develop GBS infection (controls).
Biological materials will be used for i) determining the
concentration of specific IgG anti-GBS (serotype III the
most frequent cause of neonatal disease) in the cord
Table 1 Work-Packages (WP) of the PREPARE Study: role, goals and participating countries
Work
packages
Role in the project Goals Participating
country
WP1 Project Management, Scientific
Coordination and Oversight of Capacity
Building.
To ensure conduct of all research activities to the highest standards,
including oversight and coordination of the other WPs to ensure deliverables
and milestones are met.
United
Kingdom
South Africa
WP2 Clinical trial site development and GBS
disease surveillance.
To establish the GBS disease incidence in an urban Ugandan cohort followed
to 3 months of age and establish the baseline rates of common obstetric and
neonatal outcomes in preparation for WP4 and WP5.
Uganda
South Africa
United
Kingdom
WP3 Developing serocorrelates of protection
against GBS
To develop a biobank of prospectively collected sera from cases of GBS
disease and associated GBS disease isolates from a network of African and
European sites in order to define serocorrelates of protection against GBS,
using standardized antibody assays.
Uganda,
Malawi,
South Africa,
United
Kingdom,
Italy,
France,
Netherlands
WP4 Multivalent CPS-conjugate vaccine trial. To conduct a phase II study of a multivalent vaccine against the GBS CPS in
pregnant HIV-infected and uninfected women and to establish a platform for
future trials with new GBS vaccines.
United
Kingdom
Uganda
WP5 Minervax Alp-NN GBS vaccine trial. To conduct a phase II study of a multivalent vaccine against the Alp and Rib
proteins on the surface of GBS in pregnant HIV-infected and uninfected
women and to establish a platform for future trials with new GBS vaccines.
Denmark
United
Kingdom
South Africa
WP6 Communications, networking and
dissemination.
To develop a strategy for patient and public involvement, communications,
capacity strengthening and stakeholder engagement.
United
Kingdom
CPS Capsular polysaccharide, GBS group B streptococcus
Table 2 Partner of the PREPARE Consortium
Organisation Country Role H2020
type of organisation
St George’s Hospital Medical School (SGUL) United Kingdom Coordinator Secondary or higher education establishment
Makerere University - Johns Hopkins University Care Ltd Uganda Participant Research organisation
University of Liverpool United Kingdom Participant Secondary or higher education establishment
Wits Health Consortium (PTY) LTD South Africa Participant Secondary or higher education establishment
Assistance Publique Hopitaux de Paris (AP- HP) France Participant Secondary or higher education establishment
Academisch Medisch Centrum bij de Universiteit van Amsterdam The Netherlands Participant Secondary or higher education establishment
Azienda Ospedaliero- Universitaria di Modena Italy Participant Secondary or higher education establishment
University College London (UCL) United Kingdom Participant Secondary or higher education establishment
London School of Hygiene and Tropical Medicine (LSHTM) United Kingdom Participant Secondary or higher education establishment
Minervax ApS Denmark Participant Small or medium sized entreprise
Pfizer Inc. United Kingdom Participant International Organisation
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serum of healthy controls and in the serum of infants
(aged 0 to 90 days of life) with GBS infection ii) assessing
a correlation between antibody concentration and GBS
disease risk and iii) validating estimates of protective
serocorrelates.
Conclusions
Despite the progress made in high-income countries in
the prevention of EOD, GBS remains an important cause
of morbidity and mortality in the first months of life
worldwide.
A maternal GBS vaccine could reduce the burden of
both EOD and LOD, maternal puerperal sepsis, stillbirth
and preterm delivery. A vaccine could help to overcome
the inherent limitations of IAP, and could reduce un-
necessary antibiotics, as well as costs and long-term dis-
abilities consequent to GBS infection. Finally, a vaccine
could be an effective strategy for resource-poor coun-
tries, where the antenatal screening and large-scale IAP
might be unfeasible. PREPARE aims to undertake clin-
ical trials of a maternal GBS vaccine, to determine preg-
nancy outcomes, and to estimate the protection
serocorrelates against the main GBS serotypes that cause
diseases in Europe and Africa.
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